



US010543179B2

(12) **United States Patent**  
**Boulton et al.**(10) **Patent No.:** **US 10,543,179 B2**  
(45) **Date of Patent:** **Jan. 28, 2020**(54) **DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR***G01N 33/487* (2013.01); *G06F 19/326* (2013.01); *G16H 50/20* (2018.01); *G16H 50/30* (2018.01)(71) Applicant: **Novartis AG**, Basel (CH)(72) Inventors: **Craig Boulton**, Horsham (GB); **Pascale Burtin**, Huningue (FR); **Olivier David**, Mulhouse (FR); **Ana de Vera**, Basel (CH); **Thomas Dumortier**, Basel (CH); **Irene Hunt**, Basel (CH); **Robert Schmodder**, Berkeley Heights, NJ (US); **William C. Collins**, Basel (CH)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/986,992**(22) Filed: **May 23, 2018**(65) **Prior Publication Data**

US 2018/0263929 A1 Sep. 20, 2018

**Related U.S. Application Data**

(63) Continuation of application No. 15/646,583, filed on Jul. 11, 2017, now abandoned, which is a continuation of application No. 15/152,894, filed on May 12, 2016, now abandoned, which is a continuation of application No. 14/176,504, filed on Feb. 10, 2014, now abandoned, which is a continuation of application No. 13/497,349, filed as application No. PCT/US2010/049441 on Sep. 20, 2010, now abandoned.

(60) Provisional application No. 61/246,706, filed on Sep. 29, 2009, provisional application No. 61/258,329, filed on Nov. 5, 2009, provisional application No. 61/307,992, filed on Feb. 25, 2010, provisional application No. 61/352,029, filed on Jun. 7, 2010.

(51) **Int. Cl.***A61K 49/00* (2006.01)  
*A61K 31/135* (2006.01)  
*A61K 31/137* (2006.01)  
*G06F 19/00* (2018.01)  
*A61K 31/138* (2006.01)  
*A61K 31/661* (2006.01)  
*A61K 45/06* (2006.01)  
*A61B 5/021* (2006.01)  
*A61B 5/024* (2006.01)  
*A61B 5/0402* (2006.01)  
*A61B 5/00* (2006.01)  
*G01N 33/487* (2006.01)  
*G16H 50/20* (2018.01)  
*G16H 50/30* (2018.01)(52) **U.S. Cl.**CPC ..... *A61K 31/135* (2013.01); *A61B 5/021* (2013.01); *A61B 5/024* (2013.01); *A61B 5/0402* (2013.01); *A61B 5/444* (2013.01); *A61B 5/4833* (2013.01); *A61K 31/137* (2013.01); *A61K 31/138* (2013.01); *A61K 31/661* (2013.01); *A61K 45/06* (2013.01);(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

## FOREIGN PATENT DOCUMENTS

EP	1905434	A1	4/2008
EP	1923058		5/2008
WO	WO03097028		11/2003
WO	WO2005/025553	A2	3/2005
WO	WO2006/058316	A1	6/2006
WO	WO2009/155475	A1	12/2009
WO	WO2010075239	A1	7/2010

## OTHER PUBLICATIONS

Maritime. Medical News Today [online]; 2006; downloaded from < URL <http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=53054> > on Nov. 11, 2018; 6 pages. (Year: 2006).\*

Garber. Nature Biotechnology. 2008; 26(8): 844-845. (Year: 2008).\*

Dowell, Scott F., and Joseph S. Bresee. "Severe varicella associated with steroid use." Pediatrics 92.2 (1993): 223-228.

Johnson "Etiology and Treatment of Macular Edema" American Journal of Ophthalmology, 2009;147:11-21.

Saab et al., "Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient", Arch Ophthalmol/vol. 126(No. 1) Jan. 2008.

Zuvich et al., "Genetics and Pathogenesis of Multiple Sclerosis", National Institutes of Health, Author Manuscript, 21(6), 328-333 (2009).

Multiple Sclerosis, Poster Presentations, 2008, vol. 14, p. S177.

Budde et al., "First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients", Journal of the American Society of Nephrology, 2002, vol. 13, No. 4, pp. 1073-1083.

Koyrakh et al., "The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein-Gated Potassium Channel IKACH", American Journal of Transplantation, American Society of Transplantation, 2005, vol. 5, No. 3, pp. 529-536.

Comi G. et al., "Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resuPaylts.", Mult.Scler. Feb. 2010; 16(2): 197-207. [Epub Dec. 22, 2009 Abstract [on-line] [found on Sep. 10, 2014] (found in the Internet at: [www.ncbi.nlm.nih.gov/pubmed/20028707](http://www.ncbi.nlm.nih.gov/pubmed/20028707))].

Kharkevich Pharmacology, M., Medicine, 1996, pp. 41 to 42 §6.A (English Translation ).

(Continued)

Primary Examiner — David Browe

(74) Attorney, Agent, or Firm — Baker Donelson

(57) **ABSTRACT**

The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.

**4 Claims, No Drawings**